This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

A Study of Cobimetinib in Combination With Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, and Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as First-line Treatment for Participants With Metastatic Triple-Negative Breast Cancer

This study is currently recruiting participants.
See Contacts and Locations
Verified July 2017 by Hoffmann-La Roche
Sponsor:
Information provided by (Responsible Party):
Hoffmann-La Roche
ClinicalTrials.gov Identifier:
NCT02322814
First received: December 19, 2014
Last updated: July 31, 2017
Last verified: July 2017
  Purpose
This three-cohort, multi-stage, randomized, Phase II, multicenter trial will evaluate the safety and tolerability and estimate the efficacy of cobimetinib plus paclitaxel versus placebo plus paclitaxel in Cohort I, of cobimetinib plus atezolizumab plus paclitaxel in Cohort II, and of cobimetinib plus atezolizumab plus nab-paclitaxel in Cohort III in participants with metastatic or locally advanced, triple-negative adenocarcinoma of the breast who have not received prior systemic therapy for metastatic breast cancer (MBC). Participants may continue on study treatment until the development of progressive disease (PD) or the loss of clinical benefit, unacceptable toxicity, and/or consent withdrawal. The Cohort I target sample size is 12 participants for the safety run-in stage and approximately 90 participants in the expansion stage. Each of Cohorts II and III will consist of a safety run-in stage of approximately 15 participants followed by an expansion stage of approximately 15 participants.

Condition Intervention Phase
Breast Cancer Drug: Cobimetinib Drug: Paclitaxel Drug: Placebo Drug: Atezolizumab Drug: Nab-Paclitaxel Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multistage, Phase II Study Evaluating the Safety and Efficacy of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as First-Line Treatment for Patients With Metastatic Triple-Negative Breast Cancer

Resource links provided by NLM:


Further study details as provided by Hoffmann-La Roche:

Primary Outcome Measures:
  • Cohort I: Progression-Free Survival, as Determined by Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) [ Time Frame: Randomization up to disease progression or relapse, whichever occurs first (up to approximately 3.5 years) ]
  • Cohort II, III: Percentage of Participants With Confirmed Overall Response (OR) (Partial Response [PR] or Complete Response [CR]), as Determined by the Investigator Using RECIST v1.1 [ Time Frame: Randomization up to disease progression or relapse, whichever occurs first (up to approximately 3.5 years) ]

Secondary Outcome Measures:
  • Cohort I, II, III: Overall Survival (OS) [ Time Frame: Randomization up to death from any cause (up to approximately 3.5 years) ]
  • Cohort I: Percentage of Participants With Confirmed OR (PR or CR), as Determined by the Investigator Using RECIST v1.1 [ Time Frame: Randomization up to disease progression or relapse, whichever occurs first (up to approximately 3.5 years) ]
  • Cohort I, II, III: Duration of Response (DOR), as Determined by the Investigator Using RECIST v1.1 [ Time Frame: Time from the first occurrence of documented objective response to time of relapse or death, whichever occurs first (up to approximately 3.5 years) ]
  • Cohort I, II, III: Percentage of Participants With Unconfirmed Overall Response (OR_uc) (Unconfirmed PR or CR), as Determined by the Investigator Using RECIST v1.1 [ Time Frame: Randomization up to disease progression or relapse, whichever occurs fist (up to approximately 3.5 years) ]
  • Cohort I, II, III: Percentage of Participants With Adverse Events (AEs) [ Time Frame: Randomization up to 3.5 years ]
  • Cohort II, III: Progression-Free Survival, as Determined by Investigator Using RECIST v1.1 [ Time Frame: Randomization up to disease progression or relapse, whichever occurs first (up to approximately 3.5 years) ]
  • Cohort I, II, III: Maximum Plasma Concentration (Cmax) of Cobimetinib [ Time Frame: Safety Run-In:Predose (Hour [Hr] 0) on Cycle (Cy) 1 Day (D) 8; predose (Hr 0), 0.5, 1, 2, 4, and 6 Hr postdose (2, 4 Hr postdose for CohortsII,III) on Cy1 D15; Expansion: predose (Hr 0), 1-4 Hr postdose on Cy 1 D15; predose (Hr 0) on Cy2 D15 (Cy=28days) ]
  • Cohort I, II, III: Minimum Plasma Concentration (Cmin) of Cobimetinib [ Time Frame: Safety Run-In:Predose (Hr 0) on Cy1 D8; predose (Hr 0), 0.5, 1, 2, 4, and 6 Hr postdose (2, 4 Hr postdose for CohortsII,III) on Cy1 D15; Expansion: predose (Hr 0), 1-4 Hr postdose on Cy 1 D15; predose (Hr 0) on Cy2 D15 (Cy=28days) ]
  • Cohort I, II, III: Area Under the Concentration-Time Curve From Time Zero to Dosing Interval (AUC0-tau; Total Exposure) of Cobimetinib [ Time Frame: Safety Run-In:Predose (Hr 0) on Cy1 D8; predose (Hr 0), 0.5, 1, 2, 4, and 6 Hr postdose (2, 4 Hr postdose for CohortsII,III) on Cy1 D15; Expansion: predose (Hr 0), 1-4 Hr postdose on Cy1 D15; predose (Hr 0) on Cy2 D15 (Cy=28days) ]
  • Cohort I, II: Cmax of Paclitaxel [ Time Frame: Safety Run-In: Predose (Hr 0) on Cy1 D8; predose (Hr 0), 0.5, 1, 2, 4, and 6 Hr postdose (2, 4 Hr postdose for Cohort II) (infusion duration: 1Hr) on Cy1 D15 (Cy=28days) ]
  • Cohort I, II: Cmin of Paclitaxel [ Time Frame: Safety Run-In: Predose (Hr 0) on Cy1 D8; predose (Hr 0), 0.5, 1, 2, 4, and 6 Hr postdose (2, 4 Hr postdose for Cohort II) (infusion duration: 1Hr) on Cy1 D15 (Cy=28days) ]
  • Cohort I, II: AUC0-tau of Paclitaxel [ Time Frame: Safety Run-In: Predose (Hr 0) on Cy1 D8; predose (Hr 0), 0.5, 1, 2, 4, and 6 Hr postdose (2, 4 Hr postdose for Cohort II) (infusion duration: 1Hr) on Cy1 D15 (Cy=28days) ]
  • Cohort III: Cmax of Nab-Paclitaxel [ Time Frame: Safety Run-In: Predose (Hr 0) on Cy1 D8; predose (Hr 0), 2, 4 Hr postdose (infusion duration: 30 minutes) on Cy1 D15 (Cy=28days) ]
  • Cohort III: Cmin of Nab-Paclitaxel [ Time Frame: Safety Run-In: Predose (Hr 0) on Cy1 D8; predose (Hr 0), 2, 4 Hr postdose (infusion duration: 30 minutes) on Cy1 D15 (Cy=28days) ]
  • Cohort III: AUC0-tau of Nab-Paclitaxel [ Time Frame: Safety Run-In: Predose (Hr 0) on Cy1 D8; predose (Hr 0), 2, 4 Hr postdose (infusion duration: 30 minutes) on Cy1 D15 (Cy=28days) ]
  • Cohort II, III: Cmax (in Serum) of Atezolizumab [ Time Frame: Safety Run-In, Expansion:Predose (Hr0), 0.5Hr postdose (infusion duration:1Hr) on D1 of Cy1, 3; predose (Hr0) on D1 of Cy2, 4, 8, every 8 Cy up to end of treatment (EOT) (approximately 3.5 years); 120 days after EOT (approximately 3.5 years) (Cy=28days) ]
  • Cohort II, III: Cmin (in Serum) of Atezolizumab [ Time Frame: Safety Run-In, Expansion:Predose (Hr0), 0.5Hr postdose (infusion duration:1Hr) on D1 of Cy1, 3; predose (Hr0) on D1 of Cy2, 4, 8, every 8 Cy up to EOT (approximately 3.5 years); 120 days after EOT (approximately 3.5 years) (Cy=28days) ]
  • Cohort II, III: AUC0-tau (in Serum) of Atezolizumab [ Time Frame: Safety Run-In, Expansion:Predose (Hr0), 0.5Hr postdose (infusion duration:1Hr) on D1 of Cy1, 3; predose (Hr0) on D1 of Cy2, 4, 8, every 8 Cy up to EOT (approximately 3.5 years); 120 days after EOT (approximately 3.5 years) (Cy=28days) ]

Estimated Enrollment: 162
Actual Study Start Date: November 25, 2014
Estimated Study Completion Date: July 1, 2020
Estimated Primary Completion Date: July 31, 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Cohort I: Cobimetinib, Paclitaxel
Participants will receive a combination of cobimetinib plus paclitaxel in 28-day cycles until disease progression, unacceptable toxicity, investigator decision, death, withdrawal of consent, or completion of study.
Drug: Cobimetinib
Cobimetinib will be administered orally at a dose of 60 milligrams (mg) per day, once a day, on Day 3 through Day 23 of each 28-day treatment cycle.
Other Name: GDC-0973; RO5514041; XL518
Drug: Paclitaxel
Paclitaxel will be administered at a dose of 80 mg/m^2 by IV infusion on Day 1, Day 8, and Day 15 of each 28-day cycle according to prescribing information.
Placebo Comparator: Cohort I: Placebo, Paclitaxel
Participants will receive a combination of cobimetinib placebo plus paclitaxel in 28-day cycles until disease progression, unacceptable toxicity, investigator decision, death, withdrawal of consent, or completion of study.
Drug: Paclitaxel
Paclitaxel will be administered at a dose of 80 mg/m^2 by IV infusion on Day 1, Day 8, and Day 15 of each 28-day cycle according to prescribing information.
Drug: Placebo
Cobimetinib placebo will be administered orally, once a day, on Day 3 through Day 23 of each 28 day treatment cycle.
Experimental: Cohort II:Cobimetinib,Paclitaxel,Atezolizumab
Participants will receive cobimetinib plus paclitaxel plus atezolizumab in 28-day cycles until disease progression, unacceptable toxicity, investigator decision, death, withdrawal of consent, or completion of study.
Drug: Cobimetinib
Cobimetinib will be administered orally at a dose of 60 milligrams (mg) per day, once a day, on Day 3 through Day 23 of each 28-day treatment cycle.
Other Name: GDC-0973; RO5514041; XL518
Drug: Paclitaxel
Paclitaxel will be administered at a dose of 80 mg/m^2 by IV infusion on Day 1, Day 8, and Day 15 of each 28-day cycle according to prescribing information.
Drug: Atezolizumab
Atezolizumab will be administered to Cohorts II and III at a dose of 840 milligrams (mg) intravenously (IV) every 2 weeks on Days 1 and 15 of each 28-day treatment cycle.
Experimental: Cohort III: Cobimetinib, Nab-Paclitaxel, Atezolizumab
Participants will receive cobimetinib plus nab-paclitaxel plus atezolizumab until disease progression, unacceptable toxicity, investigator decision, death, withdrawal of consent, or completion of study.
Drug: Cobimetinib
Cobimetinib will be administered orally at a dose of 60 milligrams (mg) per day, once a day, on Day 3 through Day 23 of each 28-day treatment cycle.
Other Name: GDC-0973; RO5514041; XL518
Drug: Atezolizumab
Atezolizumab will be administered to Cohorts II and III at a dose of 840 milligrams (mg) intravenously (IV) every 2 weeks on Days 1 and 15 of each 28-day treatment cycle.
Drug: Nab-Paclitaxel
Nab-Paclitaxel will be administered to Cohort III according to the local prescribing information at a starting dose of 100 millimeters per square meters (mg/m^2) by IV infusion on Days 1, 8, and 15 of each 28 day cycle.

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • Histologically confirmed estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and human epidermal growth factor 2 (HER2)-negative adenocarcinoma of the breast with measurable metastatic or locally advanced disease
  • Locally advanced disease must not be amenable to resection with curative intent
  • Measurable disease, according to RECIST, v1.1
  • Adequate hematologic and end organ function
  • Agreement to use highly effective contraceptive methods as stated in protocol

Exclusion Criteria:

  • Known HER2-, ER-, or PR-positive breast cancer by local laboratory assessment
  • Any prior chemotherapy, hormonal, or targeted therapy, for inoperable locally advanced or metastatic triple-negative breast cancer (mTNBC)
  • Any systemic anticancer therapy within 3 weeks prior to Cycle 1, Day 1
  • Any radiation treatment to metastatic site within 28 days of Cycle 1, Day 1
  • Major surgical procedure, open biopsy, or significant traumatic injury within 30 days prior to Cycle 1, Day 1 or anticipation of need for major surgical procedure during the course of the study
  • Prior exposure to experimental treatment targeting rapidly accelerated fibrosarcoma (Raf), MAP kinase/ERK kinase (MEK), or the mitogen-activated protein kinase (MAPK) pathway
  • Brain metastases (symptomatic or nonsymptomatic) that have not been treated previously, are progressive, or require any type of therapy (e.g., radiation, surgery, or steroids) to control symptoms from brain metastases within 30 days prior to first study treatment dose
  • History of or evidence of retinal pathology on ophthalmologic examination that is considered a risk factor for neurosensory retinal detachment/central serous chorioretinopathy (CSCR), retinal vein occlusion (RVO), or neovascular macular degeneration
  • Cobimetinib is metabolized by the hepatic cytochrome P450 3A4 (CYP3A4) enzyme. Drugs CYP3a4/5 inhibitors and inducers should be avoided
  • History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
  • Known hypersensitivity or allergy to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the atezolizumab formulation
  • History of autoimmune disease
  • Prior allogenic stem cell or solid organ transplantation
  • History of idiopathic pulmonary fibrosis (including pneumonitis), drug induced pneumonitis, organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia), or evidence of active pneumonitis on screening chest computed tomography (CT) scan
  • Positive test for Human Immunodeficiency Virus (HIV)
  • Active hepatitis B (defined as having a positive hepatitis B surface antigen [HBsAg] test at screening) or hepatitis C
  • Active tuberculosis
  • Receipt of a live, attenuated vaccine within 4 weeks prior to randomization or anticipation that such a live, attenuated vaccine will be required during the study
  • Prior treatment with cluster of differentiation (CD) 137 (CD137) agonists or immune checkpoint blockade therapies, including anti-cytotoxic T-lymphocyte-associated protein 4 (anti-CTLA-4), anti-programmed death-1 (anti-PD-1), or anti-programmed death ligand-1 (anti-PD-L1) therapeutic antibodies
  • Treatment with systemic immunostimulatory agents (including but not limited to interferons or Interlukin-2 [IL-2]) within 4 weeks or five half-lives of the drug (whichever is shorter) prior to randomization
  • Treatment with systemic corticosteroids or other systemic immunosuppressive medications

within 2 weeks prior to randomization, or anticipated requirement for systemic immunosuppressive medications during the trial

  • No other history of or ongoing malignancy that would potentially interfere with the interpretation of the PD or efficacy assays
  • History of clinically significant cardiac dysfunction
  • Pregnancy (positive serum pregnancy test) or lactation
  • Uncontrolled serious medical or psychiatric illness
  • Active infection requiring intravenous (IV) antibiotics on Cycle 1, Day 1
  • Participants who have a history of hypersensitivity reactions to paclitaxel or other drugs formulated in Cremophor® EL (polyoxyethylated castor oil) or to nab-paclitaxel and any of the excipients
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02322814

Contacts
Contact: Reference Study ID Number: WO29479 www.roche.com/about_roche/roche_worldwide.htm 888-662-6728 (U.S. and Canada) global-roche-genentech-trials@gene.com

  Show 91 Study Locations
Sponsors and Collaborators
Hoffmann-La Roche
Investigators
Study Director: Clinical Trials Hoffmann-La Roche
  More Information

Responsible Party: Hoffmann-La Roche
ClinicalTrials.gov Identifier: NCT02322814     History of Changes
Other Study ID Numbers: WO29479
2014-002230-32 ( EudraCT Number )
Study First Received: December 19, 2014
Last Updated: July 31, 2017

Additional relevant MeSH terms:
Breast Neoplasms
Triple Negative Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Paclitaxel
Albumin-Bound Paclitaxel
Antibodies, Monoclonal
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Immunologic Factors
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on August 18, 2017